Although there is no direct evidence that darunavir is a substrate of SLCO3A1, a 12% significantly lower Darunavir clearance was reduced in patients with SLCO3A1 variant, suggesting that this might be a substrate of darunavir and should assess COVID-19 patients (p < 0.05) (Moltó et al., 2013). Here, SLCO3A1 is linked to COVID-19.